The Biostatistics Shared Resource (BSR) of the Mayo Clinic Cancer Center (MCCC), under the leadership of Dr. Daniel Sargent, PhD (since 2001) has provided expert statistical collaboration with MCCC investigators for over 40 years for the development and conduct of peer-reviewed cancer center research encompassing basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of CCSG funds within the BSR is to support statistical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Funding is primarly provided to protect FTE of key faculty members to collaborate with MCCC members at no charge;funding is also provided to select senior MS statisticans for work on approved MCCC projects. In the current grant period the BSR has successfully and strategically firmly established high dimensional genomic and proteomic data analysis, and a robust presence at all 3 MCCC campuses. BSR faculty includes statistical methodological research leaders in clinical trial design, survival analysis, high-dimensional data, statistical genetics, quality of life research, and surrogate endpoints. The BSR has three focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, and patient and public education research projects, (11) a Population Science/Computational Genomics team responsible for statistical collaboration and data management support for high dimensional data analyses and cancer observational studies, including genetic and molecular epidemiology, and (III) a Quality of Life team responsible for collaboration, measurement tools, and analysis for MCCC investigators investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others. The BSR has been remarkably productive, with authorship on 833 peer reviewed publications and collaborations on 63 NIH or NIH-equivalent grants in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682938
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$576,349
Indirect Cost
$214,152
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:

Showing the most recent 10 out of 1086 publications